DNA Damage Response Targeting Therapeutics (Beyond PARP Inhibitors) - Current Market Landscape
During our research, we came across over 43 companies that are presently engaged in the development of DDR targeting therapeutics. There has been a significant increase in the number of developers that have been established in this domain post-2008. In fact, close to XX players were established during the period 2013-2016. Further, over XX developers have been founded since 2017.  To...
0 Comments 0 Shares
Sponsored